In patients with CRC, mutations in the PI3K/Akt pathway have emerged as an independent predictor of immunotherapy response, correlating to better OS and increased immune cell infiltration, such as M1 macrophages, neutrophils, and NK cells, within TME (230). The gene discussed is AKT1; the disease is colorectal carcinoma.